Common molecular mechanism of amyloid pore formation by Alzheimer's β-amyloid peptide and α-synuclein

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Di Scala, Coralie ^a   Yahi, Nouara ^a   Boutemeur, Sonia ^a   Flores, Alessandra ^a   Rodriguez, Lea ^a   Chahinian, Henri ^a   Fantini, Jacques ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; CALCIUM; CHOLESTEROL; CYCLODEXTRIN; GANGLIOSIDE; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN DOMAIN; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; CALCIUM; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CHOLESTEROL; CYCLODEXTRINS; GANGLIOSIDES; HUMANS; PEPTIDE FRAGMENTS; PROTEIN DOMAINS;

EID: 84976608563     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28781     Document Type: Article

References (66)

1. Hardy, J. A., Higgins, G. A. Alzheimer's disease: the amyloid cascade hypothesis. Science (New York, N.Y.) 256, 184-185 (1992).
2. Science 256, 184-185 (1992).
3. Irvine, G. B., El-Agnaf, O. M., Shankar, G. M., Walsh, D. M. Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases. Mol. Med. 14, 451-464 (2008).
4. Aguzzi, A., O'Connor, T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat. Rev. Drug Discov. 9, 237-248 (2010).
5. Walsh, D. M., Selkoe, D. J. A beta oligomers-a decade of discovery. J. Neurochem. 101, 1172-1184 (2007).
6. Haass, C., Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007).
7. Winner, B. et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. USA 108, 4194-4199 (2011).
8. Fantini, J., Yahi, N. Brain lipids in synaptic function and neurological disease. Clues to innovative therapeutic strategies for brain disorders, Elsevier Academic Press, (2015).
9. Snowdon, D. A. Aging and Alzheimer's disease: lessons from the Nun Study. Gerontologist 37, 150-156 (1997).
10. Esparza, T. J. et al. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104-119 (2013).
11. Rosenblum, W. I. Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol. Aging 35, 969-974 (2014).
12. Jang, H. et al. Alzheimer's disease: which type of amyloid-preventing drug agents to employ? Phys. Chem. Chem. Phys. 15, 8868-8877 (2013).
13. Lasagna-Reeves, C. A., Glabe, C. G., Kayed, R. Amyloid-beta annular protofibrils evade fibrillar fate in Alzheimer disease brain. J. Biol. Chem. 286, 22122-22130 (2011).
14. Glabe, C. G. Structural classification of toxic amyloid oligomers. J. Biol. Chem. 283, 29639-29643 (2008).
15. Kayed, R. et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 279, 46363-46366 (2004).
16. Quist, A. et al. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. USA 102, 10427-10432 (2005).
17. Lashuel, H. A., Hartley, D., Petre, B. M., Walz, T., Lansbury, P. T. Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291 (2002).
18. Shafrir, Y., Durell, S., Arispe, N., Guy, H. R. Models of membrane-bound Alzheimer's Abeta peptide assemblies. Proteins 78, 3473-3487 (2010).
19. Pollard, H. B., Rojas, E., Arispe, N. A new hypothesis for the mechanism of amyloid toxicity, based on the calcium channel activity of amyloid beta protein (A beta P) in phospholipid bilayer membranes. Ann. N.Y. Acad. Sci. 695, 165-168 (1993).
20. Lal, R., Lin, H., Quist, A. P. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim. Biophys. Acta 1768, 1966-1975 (2007).
21. Di Scala, C. et al. Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer beta-amyloid peptide. J. Neurochem. 128, 186-195 (2013).
22. Fantini, J. et al. Bexarotene blocks calcium-permeable ion channels formed by neurotoxic Alzheimer's beta-amyloid peptides. ACS Chem. Neurosci. 5, 216-224 (2014).
23. Micelli, S., Meleleo, D., Picciarelli, V., Gallucci, E. Effect of sterols on beta-amyloid peptide (AbetaP 1-40) channel formation and their properties in planar lipid membranes. Biophys. J. 86, 2231-2237 (2004).
24. Hong, S. et al. Soluble Abeta oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes. Neuron 82, 308-319 (2014).
25. Yanagisawa, K., Odaka, A., Suzuki, N., Ihara, Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med. 1, 1062-1066 (1995).
26. Ogawa, M. et al. Ganglioside-mediated aggregation of amyloid beta-proteins (Abeta): comparison between Abeta-(1-42) and Abeta-(1-40). J. Neurochem. 116, 851-857 (2011).
27. Oikawa, N. et al. Gangliosides determine the amyloid pathology of Alzheimer's disease. Neuroreport 20, 1043-1046 (2009).
28. Yahi, N., Fantini, J. Deciphering the glycolipid code of Alzheimer's and Parkinson's amyloid proteins allowed the creation of a universal ganglioside-binding Peptide. PloS one 9, e104751 (2014).
29. Martinez, Z., Zhu, M., Han, S., Fink, A. L. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry 46, 1868-1877 (2007).
30. Wang, S. S., Rymer, D. L., Good, T. A. Reduction in cholesterol and sialic acid content protects cells from the toxic effects of betaamyloid peptides. J. Biol. Chem. 276, 42027-42034 (2001).
31. Fantini, J., Carlus, D., Yahi, N. The fusogenic tilted peptide (67-78) of alpha-synuclein is a cholesterol binding domain. Biochim. Biophys. Acta 1808, 2343-2351 (2011).
32. Di Scala, C., Chahinian, H., Yahi, N., Garmy, N., Fantini, J. Interaction of Alzheimer's beta-Amyloid Peptides with Cholesterol: Mechanistic Insights into Amyloid Pore Formation. Biochemistry 53, 4489-4502 (2014).
33. Di Scala, C. et al. Biochemical identification of a linear cholesterol-binding domain within Alzheimer's beta amyloid peptide. ACS Chem. Neurosci. 4, 509-517 (2013).
34. Fantini, J., Yahi, N. Molecular basis for the glycosphingolipid-binding specificity of alpha-synuclein: key role of tyrosine 39 in membrane insertion. J. Mol. Biol. 408, 654-669 (2011).
35. Amer, D. A., Irvine, G. B., El-Agnaf, O. M. Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders. Exp. Brain Res. 173, 223-233 (2006).
36. Ueno, H. et al. Comparison between the aggregation of human and rodent amyloid beta-proteins in GM1 ganglioside clusters. Biochemistry 53, 7523-7530 (2014).
37. Melachroinou, K. et al. Deregulation of calcium homeostasis mediates secreted alpha-synuclein-induced neurotoxicity. Neurobiol. Aging 34, 2853-2865 (2013).
38. Arispe, N., Pollard, H. B., Rojas, E. Zn2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc. Natl. Acad. Sci. USA 93, 1710-1715 (1996).
39. Diaz, J. C., Linnehan, J., Pollard, H., Arispe, N. Histidines 13 and 14 in the Abeta sequence are targets for inhibition of Alzheimer's disease Abeta ion channel and cytotoxicity. Biol. Res. 39, 447-460 (2006).
40. Puri, A. et al. An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS 18, 849-858 (2004).
41. Di Scala, C. et al. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides. Biochim. Biophys. Acta 1862, 213-222 (2016).
42. Brasseur, R., Pillot, T., Lins, L., Vandekerckhove, J., Rosseneu, M. Peptides in membranes: tipping the balance of membrane stability. Trends Biochem. Sci. 22, 167-171 (1997).
43. Brasseur, R. Tilted peptides: a motif for membrane destabilization (hypothesis). Mol. Membr. Biol. 17, 31-40 (2000).
44. Fantini, J., Yahi, N. Molecular insights into amyloid regulation by membrane cholesterol and sphingolipids: common mechanisms in neurodegenerative diseases. Exp. Rev. Mol. Med. 12, e27 (2010).
45. Cramer, P. E. et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506 (2012).
46. Landreth, G. E. et al. Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340, 924-g (2013).
47. McFarland, K. et al. Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease. ACS Chem. Neurosci. 4, 1430-1438 (2013).
48. Tsigelny, I. F. et al. Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS J. 274, 1862-1877 (2007).
49. Rawat, S. S. et al. Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol. Membr. Biol. 20, 243-254 (2003).
50. Fantini, J., Hammache, D., Pieroni, G., Yahi, N. Role of glycosphingolipid microdomains in CD4-dependent HIV-1 fusion. Glycoconjugate J. 17, 199-204 (2000).
51. Nieva, J. L., Nir, S., Muga, A., Goni, F. M., Wilschut, J. Interaction of the HIV-1 fusion peptide with phospholipid vesicles: different structural requirements for fusion and leakage. Biochemistry 33, 3201-3209 (1994).
52. Nir, S., Nieva, J. L. Interactions of peptides with liposomes: pore formation and fusion. Prog. Lipid Res. 39, 181-206 (2000).
53. Blumenthal, R., Durell, S., Viard, M. HIV entry and envelope glycoprotein-mediated fusion. J. Biol. Chem. 287, 40841-40849 (2012).
54. Charloteaux, B., Lorin, A., Brasseur, R., Lins, L. The "Tilted Peptide Theory" links membrane insertion properties and fusogenicity of viral fusion peptides. Protein Pept. Lett. 16, 718-725 (2009).
55. Lorin, A., Charloteaux, B., Lins, L., Brasseur, R. Implication des peptides de fusion des glycoproteines de fusion virales de classe I dans la fusion membranaire. Biotechnol. Agron. Soc. Environ. 11, 313-335 (2007).
56. Fantini, J., Garmy, N., Mahfoud, R., Yahi, N. Lipid rafts: structure, function and role in HIV, Alzheimer's and prion diseases. Exp. Rev. Mol. Med. 4, 1-22 (2002).
57. Radhakrishnan, A., Anderson, T. G., McConnell, H. M. Condensed complexes, rafts, and the chemical activity of cholesterol in membranes. Proc. Natl. Acad. Sci. USA 97, 12422-12427 (2000).
58. Puri, A. et al. The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 95, 14435-14440 (1998).
59. Lai, A. L., Moorthy, A. E., Li, Y., Tamm, L. K. Fusion activity of HIV gp41 fusion domain is related to its secondary structure and depth of membrane insertion in a cholesterol-dependent fashion. J. Mol. Biol. 418, 3-15 (2012).
60. Yang, S. T., Kiessling, V., Simmons, J. A., White, J. M., Tamm, L. K. HIV gp41-mediated membrane fusion occurs at edges of cholesterol-rich lipid domains. Nat. Chem. Biol. 11, 424-431 (2015).
61. Pillot, T. et al. Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. J. Biol. Chem. 271, 28757-28765 (1996).
62. Crowet, J. M. et al. Tilted properties of the 67-78 fragment of alpha-synuclein are responsible for membrane destabilization and neurotoxicity. Proteins 68, 936-947 (2007).
63. Ji, S. R., Wu, Y., Sui, S. F. Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. J. Biol. Chem. 277, 6273-6279 (2002).
64. Jang, H. et al. Structural convergence among diverse, toxic beta-sheet ion channels. J. Phys. Chem. B 114, 9445-9451 (2010).
65. Jang, H. et al. Disordered amyloidogenic peptides may insert into the membrane and assemble into common cyclic structural motifs. Chem. Soc. Rev. 43, 6750-6764 (2014).
66. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).